Effects of comprehensive oral care on nasogastric tube removal in long-term care residents with dysphagia: A multi-center randomized controlled trial.

Arch Gerontol GeriatrJul 2, 2026 (epub)
Clinical ResearchGeriatricsGastroenterology

Ming-Yen Hsiao, Pei-Hsuan Shih, Tyng-Guey Wang

✦ AI-curated · Sources linked

In 30 seconds

This multicenter randomized controlled trial assessed the impact of comprehensive oral care (COC) on nasogastric (NG) tube removal in long-term care residents with dysphagia. The study involved 77 participants, with the COC group showing a significantly higher NG tube removal rate of 16.7% compared to 0% in the control group (p = 0.005) after six months, alongside improved swallowing function.

Key findings

  • The COC group had an NG tube removal rate of 16.7% vs. 0% in the control group (p = 0.005).
  • Eight participants in the COC group achieved full oral intake (p = 0.005).
  • Functional Oral Intake Scale scores were significantly higher in the COC group (p = 0.005).
  • No significant differences in body weight change or pneumonia incidence were observed between groups.

Why it matters

Improving swallowing function and facilitating NG tube removal can enhance the quality of life for residents with dysphagia in long-term care settings. This study provides evidence for the potential benefits of comprehensive oral care.

Source

PubMed · PMID 42472523

Published in Arch Gerontol Geriatr. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Geriatrics

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.